Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Children With Juvenile Idiopathic Arthritis Subtypes (ERA and JPsA)
NCT04527380Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of ixekizumab in enthesitis-related juvenile idiopathic arthritis (ERA) and juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving Juvenile Idiopathic Arthritis American College of Rheumatology 30 at 16 weeks. Started Apr 2021; status: active, not recruiting.
02
Drugs
ixekizumab
03
Conditions
enthesitis-related juvenile idiopathic arthritis (ERA)juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT04527380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527380.